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Use of Glucagon to Prevent and Treat Fatty Liver
in Transition Dairy Cows
A.S. Leaflet R1903
Donald C. Beitz, Distinguished Professor of Agriculture,
Jerry W. Young1, Professor of Animal Science Emeritus,
Arnold R. Hippen2, Assistant Professor of Dairy Science,
and Rafael Nafikov, Research Assistant
Summary and Implications
Because of the relationship of fatty liver to increase
health problems and decreased productive and reproductive
performance, scientists can improve the profitability of
dairy farmers by developing nutritional and management
technologies for preventing and treating fatty liver.  Our
research group has demonstrated that glucagon shows much
promise for use in preventing and treating fatty liver in
transition cows.  Moreover, we have data to indicate that
ultrasound technology can be used to estimate the incidence
of fatty liver within a dairy herd.  The development of a
slow-release form of glucagon would seem necessary before
adoption of our proposed glucagon technology is adopted by
the dairy industry.
Introduction
Fatty liver is a major metabolic disease of animals and
humans.  The disorder occurs when the uptake and de novo
synthesis of fatty acids exceeds the oxidation and secretion
of fatty acids in the liver.  The excess fatty acids accumulate
in the liver as triacylglycerols (TAGs).  This accumulation
is of significance because it negatively affects critical
metabolic functions of the liver.  In dairy cattle, this
condition is known as fat cow syndrome or fatty liver.  Fatty
liver occurs primarily in the first four weeks after calving
and may lead to development of lactation ketosis.  Although
data are limiting, up to 50% of all cows have an
accumulation of TAG in liver.  What is the primary event
that initiates this accumulation of TAG in liver?  The
primary cause is that the energy intake of postparturient
(transition) dairy cows is insufficient to meet the demands
for maintenance and for the increasing lactation.  This
energy deficit, and thus glucose shortage, causes a series of
metabolic adaptations that result in markedly greater rates of
mobilization of fatty acids from adipose tissue to liver and
other organs, resulting in an increased probability of fatty
liver development.
Severity of fatty liver can be defined on the basis of
amount of TAG accumulation.  My colleagues and I
commonly categorize fatty liver into normal liver (< 2%
TAG), mild (2-5% TAG), moderate (5-10% TAG), and
severe (> 10% TAG) fatty liver.  Total lipid content of liver
would be about 2% greater because of the presence of
phospholipids, cholesterol, and cholesteryl esters.  Knowing
the severity of fatty liver in cows at any given time can only
be determined by collecting a sample of liver by biopsy and
by performing a chemical analysis of that sample.  Our
research group has been studying a noninvasive procedure
involving ultrasonography.  To date, results for use of
commonly available ultrasound instruments to estimate
degree of fatty liver development seem promising.
The reason to be concerned about fatty liver
development is that fatty liver has detrimental effects on
health status, well-being, productivity, and reproductive
performance of cows.  Thus, fatty liver costs U.S. dairymen
millions of dollars each year in lost income because of
increased veterinary costs, longer calving intervals,
decreased milk production, and decreased average lifetime.
Our research group has studied the pathology and etiology
of fatty liver and ketosis, metabolic diseases that often
results from fatty liver, for over 20 years to provide a basic
understanding of the disorders and to find possible
treatments and preventatives.  Our most recent research has
led to the development of the technology of using the
pancreatic hormone called glucagon as a treatment and a
preventative.
Etiology of Fatty Liver
Although much remains to be learned about all of the
causes (etiology) of fatty liver, the major metabolic
pathways that are altered during fatty liver development are
illustrated in Figure 1.  As stated earlier, the energy or
glucose deficit that frequently occurs during the early
postparturient period causes a marked increase in the
mobilization of fatty acids (NEFA; nonesterified fatty acids)
from the stored TAG in the adipose tissue.  The NEFA
diffuse into the blood and provide energy to tissues
throughout the body.  Many NEFA diffuse into the liver
where they provide energy via oxidation to CO2 for liver
function.  If more NEFA arrive at the liver than needed for
energy purposes, the excess may be oxidized incompletely
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and generate ketone bodies (β-hydroxybutyrate,
acetoacetate, and acetone) for release to the blood.  Ketone
bodies are oxidized as a fuel by all muscles of the body.  If
ketone bodies accumulate in blood because of
overproduction, symptoms of lactation ketosis begin to
appear.  Excess NEFA in liver also are converted to TAG
for disposition.  Excessive NEFA disposal by TAG
synthesis is protective to the liver because excessive NEFA
in liver cells disrupts normal liver function.  Under normal
conditions, TAG are secreted from the liver as very-low-
density lipoproteins (VLDL).  Inadequate secretion of
VLDL, however, contributes to development of fatty liver.
An additional metabolic adaptation during the postparturient
energy deficit period is that amino acids (dietary and
mobilized) that serve as glucose precursors may become
limiting for VLDL synthesis, further contributing to fatty
liver development.
In summary, the previously mentioned metabolic
changes occur in response to a number of changes in
secretion and concentrations of hormones and growth
factors such as insulin, glucagon, and glucocorticoids that
are caused primarily by the postparturient energy deficit.
Theories have been proposed that a glucose deficiency is the
initial metabolic change that causes the hormonal and
metabolic changes that result in fatty liver development.
Our recent glucagon research resulted in us becoming
the first to develop a cure or treatment for bovine fatty liver
by using continuous 14-day intravenous infusions of
glucagon.  We also developed a preventative for fatty liver
by using subcutaneous injections of glucagon every 8 hours
for 14 days starting on day 2 postpartum (Nafikov et al.,
2002).  First, I will describe our experiments that
demonstrated that glucagon is an effective treatment for
bovine fatty liver.  Then, I will describe the experiment that
indicates glucagon is a preventative of fatty liver in dairy
cows.
Treatment of fatty liver by glucagon
An experiment was designed to test the ability of
glucagon to alleviate (or treat) fatty liver in early
postparturient (transition) dairy cows.  Twenty multiparous
(two or more lactations) Holstein cows were fed about 5 kg
of cracked corn daily in addition to their normal diet during
the final 30 days before calving to increase susceptibility to
fatty liver.  From 14 to 42 days postpartum, all cows were
fed 80% of their expected feed intake and were fed up to
one liter of 1,3-butanediol to induce fatty liver and ketosis.
To test glucagon as a treatment for fatty liver, either
glucagon at 10 mg per day or carrier (control) was infused
continuously via the jugular vein from 21 to 35 days
postpartum.  All cows had fatty liver at 14 days postpartum
and had elevated concentrations of ketone bodies and lower
glucose concentrations in plasma during the induction of
fatty liver and ketosis.  Glucagon increased the glucose
concentration in blood by about 1.4 fold throughout the 14-
day treatment period.  The increased glucose in blood
occurred because of increased rates of mobilization of
glucose from liver glycogen to the blood increased rates of
glucose synthesis from 1) primarily propionate derived from
the rumen and 2) from amino acids derived from the
digestive tract, and 3) from body proteins.  Insulin
concentrations were abnormally low during the treatment
period, and glucagon concentration was elevated as
expected.  The concentrations of β-hydroxybutyrate and
NEFA in plasma were decreased by glucagon.
But, what happened to the concentration of lipid in the
liver during the early postpartum period?  At six days
postpartum, liver TAG averaged 12.9% of liver weight
(Figure 2).
Glucagon had decreased the TAG content of livers by
71% at 35 days postpartum or after 14 days of glucagon
treatment.  The concentration of TAG in the liver of control
cows had not changed during the same 14-day period.
Therefore, our results document that glucagon decreases the
degree of fatty liver in early lactation cows, which also
decreases the incidence of ketosis after alleviation of fatty
liver.  For commercialization of glucagon treatment for fatty
liver, however, a slow-release preparation of glucagon
would be much more desirable than the infusion procedure
of our experiment.
Prevention of fatty liver by glucagon
Our research group hypothesized that, if glucagon
would increase the rate of removal of TAG from liver
(treatment), it also would lessen the increase in TAG during
the early postparturient period.  An experiment was
designed whereby we administered glucagon at day 2
postpartum to determine whether glucagon lessened or
prevented TAG accumulation.  Twenty multiparous
Holstein cows were selected during their dry period.  They
were fed supplemental cracked corn in addition to their
normal diet for the last 30 days before calving to increase
the probability that cows would develop pathological fatty
liver during the early postpartal period.  At parturition, they
were assigned randomly to one of three treatment groups of
eight cows in each.  Each cow was injected subcutaneously
with either 0.15 M sodium chloride solution (saline), 7.5 mg
of glucagon, or 15 mg of glucagon daily for 14 days starting
at day 2 postpartum.  The daily dosage of glucagon was
divided into three dosages that were injected subcutaneously
between the third and fourth rib every 8 hours to maintain
an elevated concentration of glucagon throughout the day
for the 14-day treatment period.
Glucagon at both dosages increased blood glucose
concentrations but did not alter NEFA concentrations in
blood.  The elevation in blood glucose was expected, but the
lack of effect of glucagon at our chosen dosages on plasma
NEFA was unexpected because of the well documented
observation that glucagon promotes fatty acid mobilization
from adipose tissues of nonruminant animals.  In fact,
NEFA concentrations tended to decrease because of the
Iowa State University Animal Industry Report 2004 Dairy
glucagon administration to dairy cows.  We observed that
glucagon administered at day 2 postpartum prevented the
accumulation of total lipids in liver of the transition dairy
cows during the first 2 weeks after calving (Figure 3).  Both
dosages had similar effects.  Currently, we are evaluating
the interaction of feeding glycerol, a glucose precursor, with
glucagon as a preventative of fatty liver in the transition
dairy cow.
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Figure 1. Etiology of fatty liver. TAG = triacylglycerol, NEFA
= nonesterified fatty acid, VLDL = very-low-density lipoproteins,
and HDL = high-density lipoproteins.
Iowa State University Animal Industry Report 2004 Dairy
Figure 2.  Treatment of fatty liver by glucagon.  Data for control cows
are indicated by open (o) circles; those for glucagon-treated cows are
indicated by closed () circles.  Ketosis induction period began on day
14 and concluded on day 42.  Glucagon infusion occurred from day 21
to day 35.
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Figure 3.  Prevention of fatty liver by glucagon.  Glucagon (7.5 and 15
mg daily) was injected subcutaneously three times per day from day 2 to day 16.
